In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

Andrew Hantel, MD, discusses results of a study on racial disparities in acute myeloid leukemia trials. :27

Christine McMahon, MD, discusses results of the phase 3 ASC4FIRST study, which examined asciminib versus tyrosine kinase inhibitors for patients with newly diagnosed chronic-phase CML. 3:30

Andrew Hantel, MD, discusses researching inequities in acute myeloid leukemia treatment in historically marginalized communities. 4:35

Christine McMahon, MD, presents results of a randomized trial of a care model for patients with acute myeloid leukemia and myelodysplastic syndrome. 7:09

Christine McMahon, MD, highlights the ACCESS study into post-transplant graft-versus-host disease, which produced “impressive” rates of post-transplant overall survival at 1 year. 10:22

Read the full coverage here:

https://www.healio.com/news/hematology-oncology/20240625/video-a-patients-raceethnicity-affects-eligibility-for-acute-myeloid-leukemia-trials

https://www.healio.com/news/hematology-oncology/20240620/video-strong-results-for-asciminib-in-chronic-myelogenous-leukemia

https://www.healio.com/news/hematology-oncology/20240625/video-treatment-delays-do-not-lead-to-acute-myeloid-leukemia-survival-disparities

https://www.healio.com/news/hematology-oncology/20240620/video-palliative-care-model-increases-quality-of-life-for-patients-with-leukemia

https://www.healio.com/news/hematology-oncology/20240620/video-study-produces-impressive-posttransplant-graftversushost-disease-survival-rates

Disclosures:

Hantel reports no relevant financial disclosures.

McMahon reports receiving institutional funding from Syndax and Syros and serving on a safety monitoring committee for Kura Oncology.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 ASCO Annual Meeting with a focus on leukemia, as well as Healio’s top headlines from the meeting.

Jorge E. Cortes, MD, discusses how asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia. :27

Oreofe O. Odejide, MD, MPH, highlights the importance of this study. 3:30

Read the full coverage here:

https://www.healio.com/news/hematology-oncology/20240531/asciminib-may-transform-treatment-paradigm-for-chronic-myeloid-leukemia

New approach ‘redefining what is a suitable donor’ for stem cell transplant

Source: Al Malki MM, et al. Abstract 6503. Presented at: ASCO Annual Meeting; May 30 – June 4, 2024; Chicago.

Disclosures:

Cortes reports research funding to his institution from or consultant/advisory roles with Gilead Sciences, Jazz Pharmaceuticals, Novartis, Pfizer, Takeda and other companies.

In this episode of Meeting Mic, we bring you Healio’s top headlines from ACG 2023.

Paul Feuerstadt, MD, FACG, AGAF, discusses data that link health-related quality of life and microbiome composition among patients with recurrent Clostridioides difficile infection. :38

Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial for ulcerative colitis. 7:52

Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response patients with ulcerative colitis. 12:08

Paul Feuerstadt also discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics. 15:32

Thomas F. Imperiale, MD, discusses the results of the BLUE-C study, which evaluated the clinical performance of Cologuard, a next-generation, multitarget stool DNA test. 21:08

Read the full coverage here:

https://www.healio.com/news/gastroenterology/20231023/video-rebyota-not-only-shuts-down-recurrence-also-affects-quality-of-life-in-c-diff

https://www.healio.com/news/gastroenterology/20231025/video-risankizumab-a-great-option-for-patients-induces-clinical-remission-in-uc

https://www.healio.com/news/gastroenterology/20231024/video-more-than-75-of-uc-patients-achieve-clinical-response-at-24-weeks-with-tremfya

https://www.healio.com/news/gastroenterology/20231025/video-future-is-now-here-for-recurrent-c-difficile-thanks-to-live-biotherapeutics

https://www.healio.com/news/gastroenterology/20231025/sensitivity-of-nextgeneration-cologuard-in-precancer-detection-numerically-exceeded-fit

Disclosures:

Feuerstadt reports financial relationships with Ferring Pharmaceuticals, Regeneron Pharmaceuticals, Seres Therapeutics and Takeda Pharmaceuticals. Imperiale reports grant and research support from Exact Sciences. Loftus reports financial relationships with AbbVie, Alvotech, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Exact Sciences, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Scopes, Janssen, KSL Diagnostics, Lilly, Morphic, Ono Pharma, Pfizer, Protagonist, Receptos, Robarts Clinical Trials, Scipher Medicine, Sun Pharma, Surrozen, Takeda, Theravance and UCB. Wehkamp reports no relevant financial disclosures.

In this episode of Meeting Mic, we bring you Healio’s top headlines from DDW 2023.

Jessica R. Allegretti, MD, MPH, reviews the results of a Tremfya study presented at the meeting. :09

Ken Blount, PhD, discusses restoration of gut microbiota and clonal engraftment after treatment with Rebyota. 4:07

Evan S. Dellon, MD, MPH, explains the improvements of mepolizumab seen in patients with eosinophilic esophagitis. 10:50

Jessica R. Allegretti also discusses the treatment with Rebyota in patients with inflammatory bowel disease and recurrent Clostridioides difficile infection. 15:16

Shrujal Baxi, MD, MPH, describes the use of artificial intelligence for polyp detection for colorectal cancer. 19:26

Paul Limburg, MD, MPH, AGAF, reviews the revised guidelines and the push for non-invasive screening methods for colorectal cancer. 24:07

Read the full coverage here:

https://www.healio.com/news/gastroenterology/20230509/video-patients-with-uc-achieve-symptomatic-remission-as-early-as-week-4-with-tremfya

https://www.healio.com/news/gastroenterology/20230509/video-distinctive-shift-in-gut-microbiota-after-rebyota-treatment-for-c-difficile

https://www.healio.com/news/gastroenterology/20230510/video-mepolizumab-for-eoe-does-not-yield-prominent-symptom-improvement-after-6-months

https://www.healio.com/news/gastroenterology/20230509/video-no-change-in-concomitant-medications-after-rebyota-for-recurrent-c-difficile-ibd

In this episode of Meeting Mic, we bring you expert insights from the ASH Annual Meeting and Exhibition.

Mikkael A. Sekeres, MD, MS, chief of the division of hematology and professor of medicine at Sylvester Comprehensive Cancer Center and University of Miami Health System and chair of the ASH committee on communications, discusses some key take-home points from the Long COVID presentation. :00

Shakira J. Grant, MBBS, discusses multilevel interventions required to increase the rate at which Black individuals participate in hematology research studies. 3:44

Arushi Khurana, MBBS, reviews criteria used to disqualify patients from participating in front-line clinical trials, the acceptable ranges of which often prohibited Black and Hispanic patients from enrollment. 6:35

Tatyana Feldman, MD, discusses how the addition of brentuximab vedotin and nivolumab to doxorubicin and dacarbazine appeared active among patients with advanced-stage classical Hodgkin lymphoma. 9:32

Warren B. Fingrut, MD, reviews how hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry. 12:02

Read the full coverage here:

Restrictive diet an 'unnecessary burden' for patients undergoing HSCT

Multilevel interventions needed to reduce racial disparities in clinical trial enrollment

Eligibility criteria more likely to exclude minorities from lymphoma clinical trials

Combination ‘promising’ for advanced classical Hodgkin lymphoma

Non-European HSCT recipients undergo more complex procedures with fewer resources

Disclosures:

Feldman reports consulting/advisory roles with, speakers bureau roles with or other financial relationships with AbbVie, ADC Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genmab, Genomic Testing Cooperative, Janssen, Karyopharm Therapeutics, Kite Pharma, MorphoSys, Pharmacyclics, Secura Bio, Seagen and Takeda. Please see the abstract for all other researchers’ relevant financial disclosures.

Fingrut reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures.

Grant reports no relevant financial disclosures. Please see the abstract for all other researchers’ relevant financial disclosures.

Khurana reports no relevant financial disclosures.

In this episode of Meeting Mic, we bring you the highlights and insights from the ACR Convergence 2022, as well as Healio’s top headlines from the meeting.

Virginia G. Kaklamani, MD, DSc, professor of medicine in the division of hematology/oncology at UT Health San Antonio and leader of the breast cancer program at UT Health San Antonio MD Anderson Cancer Center, reviews an abstract presentation on the impact of cyclin-dependent kinase 4/6 inhibitor therapy in patients with advanced breast cancer :00

Aditya Bardia, MD, MPH, director of the breast cancer research program at Massachusetts General Hospital and associate professor of medicine at Harvard Medical School, discusses a study on trastuzumab-deruxtecan and its response rate in patients with early breast cancer 5:00

Sara A. Hurvitz, MD, FACP, medical oncologist at UCLA Health, Santa Monica Medical Center, associate professor at David Geffen School of Medicine at UCLA, medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, and director of the breast cancer clinical trials program at UCLA, examines trastuzumab-deruxtecan’s effect on patients with breast cancer who were previously treated with trastuzumab and a taxane. 10:00

Read the full coverage here:

Longer CDK 4/6 inhibitor therapy enhances elacestrant benefit in metastatic breast cancer

Elacestrant extends PFS among certain women with metastatic breast cancer

Trastuzumab deruxtecan ‘new gold standard’ in second line for breast cancer subset

Ribociclib regimen may be superior to chemotherapy in advanced breast cancer

Breast cancer specialist receives lecture award

Genomic assay may predict ovarian function suppression benefit in breast cancer subset

Disclosures:

Bardia reports research funding from or consultant/advisory roles with AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Immunomedics/Gilead Sciences, Merck, Novartis, Pfizer, Radius Health and Sanofi.

Hurvitz reports honoraria from Daichi Sankyo and research funding to her institution from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, CytomX Therapeutics, Daiichi Sankyo, Dantari, Dignitana, Eli Lilly, G1 Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Immunomedics, MacroGenics, Novartis, OBI Pharma, Orinoco Pharmaceuticals, Pfizer, Phoenix Molecular Designs, Pieris Pharmaceuticals, Puma Biotechnology, Radius Health, Samumed, Sanofi, Seagen and Zymeworks. She also reports her spouse is a shareholder/stockholder in Ideal Implant.

Kaklamani reports honoraria from, consultant/advisory roles with, speakers bureau roles with or other relationships with AstraZeneca, Daiichi Sankyo, Genentech, Genomic Health, Gilead Sciences, Novartis, Pfizer and Puma Biotechnology. Please see the abstract for all other researchers’ relevant financial disclosures.